Combination Therapy with Ezetimibe: An Alternative Strategy to Statin Monotherapy in the Management of Patients with Non-cardiac Vascular Disease-Reference-Cited by-同舟云学术

Combination Therapy with Ezetimibe: An Alternative Strategy to Statin Monotherapy in the Management of Patients with Non-cardiac Vascular Disease

Published:2022-11 Issue:6 Volume:20 Page:457-459
ISSN:1570-1611
Container-title:Current Vascular Pharmacology
language:en
Short-container-title:CVP

Author:

Paraskevas Kosmas I.¹^ORCID,Suri Jasjit S.²,Saba Luca³,Mikhailidis Dimitri P.⁴

Affiliation:

1. Department of Vascular Surgery, Central Clinic of Athens, Athens, Greece

2. Stroke Monitoring and Diagnostic Division, AtheroPoint™, Roseville, CA, U.S.A

3. Department of Radiology, Azienda Ospedaliero Universitaria (A.O.U.) di Cagliari, Cagliari, Italy

4. Department of Clinical Biochemistry and Department of Surgical Biotechnology, Division of Surgery and Interventional Science, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London, WC1E 6BT, UK

Abstract

Publisher

Bentham Science Publishers Ltd.

Subject

Cardiology and Cardiovascular Medicine,Pharmacology

Reference12 articles.

1. Kim B.K.; Hong S.J.; Lee Y.J.; Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): A randomised, open-label, non-inferiority trial. Lancet 2022,400(10349),380-390

2. Abushamat L.A.; Ballantyne C.M.; Lowering LDL cholesterol in clinical practice: Time for change? Lancet 2022,400(10349),341-343

3. Paraskevas K.I.; Veith F.J.; Mikhailidis D.P.; Carotid intima-media thickness and ezetimibe: The end of a misunderstanding? Curr Vasc Pharmacol 2011,9(4),381-384

4. Cannon C.P.; Blazing M.A.; Giugliano R.P.; Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015,372(25),2387-2397

5. Wang N.; Fulcher J.; Abeysuriya N.; Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: A systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol 2020,8(1),36-49

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefits of Statins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) Inhibitors for Patients with Peripheral Arterial Disease;Current Vascular Pharmacology;2024-01

2. Economics of Artificial Intelligence in Healthcare: Diagnosis vs. Treatment;Healthcare;2022-12-09